NanoPhoria is a preclinical stage biotech company pioneering inhalable cardiovascular treatments via non-viral nano-delivery of biologics. The Company is devoted to the clinical development of an innovative proprietary platform for the tissue-directed delivery of therapeutic peptides and RNAs. The core vehicle is an inorganic calcium-phosphate nanoparticle which represents a versatile, biomimetic nano-carrier that can be loaded or surface decorated with biologics and can be formulated for inhalation or for other administration routes. NanoPhoria’s lead product, NP-MP1 is an inhalable nano-in-micro formulation, delivering a proprietary peptide, first-in-class calcium channel modulator, for the treatment of Heart Failure with reduced Ejection Fraction, a chronic syndrome affecting the lives of millions worldwide.
Location: Italy
Total raised: $115.98M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.10.2025 | Series A | $97.65M | Panakes Pa... |
| 26.02.2025 | - | $18.33M | - |
Mentions in press and media 11
| Date | Title | Description |
| 02.04.2026 | From fragmented funding to growing maturity: the Italian tech ecosystem | Italy’s tech funding landscape in 2025 appears larger and more mature, but also highly concentrated. Total funding of around €2.5 billion is driven by a small number of very large rounds, while most deals remain relatively small, indicating... |
| 09.03.2026 | Advancing cardiovascular health – SignaCor Therapeutics lands €288k investment as pat of €1.1 million Seed round | Darach Neeson, CEO at SignaCor, says: “The Spark programme’s content was exceptional – value-filled insights from UK life science industry experts and meaningful investor engagement. The lessons learned have influenced our strategy, and we ... |
| 11.01.2026 | Engitix Secures $25M to Advance Cancer, Fibrosis Therapies | British biotech innovator Engitix recently secured a significant $25 million Series A extension. Netherton Investments, acting for Mike Platt, drove this key financing. The capital fuels Engitix’s advanced extracellular matrix (ECM)-targete... |
| 08.01.2026 | London’s Engitix secures €21 million extension to advance ECM-targeted cancer and fibrosis therapies | Engitix, a British BioTech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a €21 million ($25 million) Series A extension financing. The financing ... |
| 10.10.2025 | n8n raises $180M, Qualcomm acquires Arduino, and Europe’s tech rebounds to €21B in Q3 2025 | This week we tracked more than 65 tech funding deals worth over €1.1 billion, and over 15 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the most i... |
| 06.10.2025 | Heidi Closes $65M Series B Funding | Heidi, a Melbourne, Australia-based healthcare AI company, raised $65M in Series B funding. The round was led by Point72 Private Investments with participation from Blackbird, Headline, and Latitude, the growth fund of Phoenix Court. The co... |
| 06.10.2025 | NanoPhoria closes €83.5 million Series A for its heart failure candidate – one of Italy’s largest 2025 BioTech rounds | Milan-based NanoPhoria Bioscience today announced the successful first close of its €83.5 million Series A financing round – the largest ever Series A round in Italian BioTech history – for its lung-to-heart drug delivery platform. The roun... |
| 06.10.2025 | NanoPhoria Bioscience Raises €83.5M in Series A Funding | NanoPhoria Biosciences, a Milan, Italy-based biotech company developing a nano-in-micro and lung-to-heart delivery platform, raised €83.5M in Series A funding. The round was led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, ... |
| 26.02.2025 | NanoPhoria Bioscience Receives €17.5M Award From EIC Accelerator Program | NanoPhoria Bioscience, a Milan, Italy-based pre-clinical stage biotech company, received a €17.5M award from EIC accelerator program, including a grant of €2.5M and a conditional equity investment of up to €15M. The company intends to use t... |
| 12.05.2022 | Sofinnova Partners Announces New Investment In Nanophoria, Developer Of An Innovative Non-viral Drug Delivery Platform | Milan-based NanoPhoria raised €3.5 million in seed financing to advance its pre-clinical stage treatment for heart failure MILAN, ITALY / ACCESSWIRE / May 12, 2022 / Sofinnova Partners, a leading European life sciences venture capital firm ... |
Show more